US Patent

US7576061 — Methods for preventing mitochondrial permeability transition

Composition of Matter · Assigned to Institut de Recherches Cliniques de Montreal IRCM · Expires 2027-01-20 · 1y remaining

Vulnerability score 35/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a method of reducing or preventing mitochondrial permeability transition by administering an aromatic-cationic peptide.

USPTO Abstract

The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p m ) and the total number of amino acid residues (r) wherein 3p m is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p t ) wherein 2a is the largest number that is less than or equal to p t +1, except that when a is 1, p t may also be 1.

Drugs covered by this patent

Patent Metadata

Patent number
US7576061
Jurisdiction
US
Classification
Composition of Matter
Expires
2027-01-20
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Institut de Recherches Cliniques de Montreal IRCM
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.